Unique characteristics of new complete blood count parameters, the Immature Platelet Fraction and the Immature Platelet Fraction Count, in dengue patients. by Yasuda, Ikkoh et al.
RESEARCH ARTICLE
Unique characteristics of new complete blood
count parameters, the Immature Platelet
Fraction and the Immature Platelet Fraction
Count, in dengue patients
Ikkoh YasudaID
1,2,3, Nobuo Saito1,2,4*, Motoi Suzuki2,5, Dorcas Valencia Umipig6,
Rontgene M. Solante6, Ferdinand De Guzman6, Ana Ria Sayo6, Michio Yasunami2,7,
Nobuo KoizumiID
8, Emi Kitashoji2, Kentaro Sakashita1,9, Chris Fook Sheng Ng1,
Chris Smith1,10, Koya Ariyoshi1,2
1 School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan, 2 Department of
Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan, 3 Department of
General Internal Medicine and Clinical Infectious Diseases, Fukushima Medical University, Fukushima,
Japan, 4 Department of Microbiology, Oita University Faculty of Medicine, Oita, Japan, 5 Infectious Disease
Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan, 6 San Lazaro Hospital, Manila,
The Philippines, 7 Saga-Ken Medical Centre Koseikan, Saga, Japan, 8 Department of Bacteriology I,
National Institute of Infectious Diseases, Toyama, Shinjuku-ku, Tokyo, Japan, 9 Department of Basic
Mycobacteriology, Graduate School of Biomedical Science, Nagasaki University, Nagasaki, Japan,




The advanced platelet parameters Immature Platelet Fraction and Immature Platelet Frac-
tion Count have been implemented in clinical practice as measures of thrombopoietic activ-
ity, mainly in hematologic disorders that cause thrombocytopenia. The purpose of this
observational study was to examine thrombopoiesis as reflected by these 2 new CBC
parameters in patients infected with dengue. The study was conducted in infectious disease
referral hospital in Metro Manila, the Philippines. We enrolled hospitalized patients at admis-
sion who were diagnosed with acute dengue or community acquired bacterial infection
(CABI). Immature Platelet Fraction (IPF) and Immature Platelet Fraction Count were evalu-
ated at admission and during hospitalization. A total of 606 patients were enrolled from May
1, 2017 to June 1, 2018. The participants consisted of 152 patients with dengue infection,
180 confirmed CABI, and 274 suspected CABI patients. At admission, the percent IPF (IPF
%) of the patients with dengue was significantly higher than that of the confirmed CABI
patients (median 3.7% versus 1.9%; p <0.001). In a time course evaluation, there was no
significant difference of IPF% between the patients with dengue infection and the confirmed
CABI patients in the febrile phase (median 1.9% versus 2.4%; p = 0.488), however, the IPF
% of the patients with dengue infection increased to be significantly higher than that of the
confirmed CABI patients in the critical phase (median 5.2% versus 2.2%; p <0.001). Our
study elucidated the unique characteristics and time-course trends of IPF percent and num-
ber (IPF#) in the patients with dengue infection. IPF% and IPF# are potentially valuable
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parameters in dengue and further investigation is required for the optimal use in clinical
practice.
Introduction
Dengue is a mosquito-borne viral infection and is one of the most important viral diseases in
tropical areas [1, 2]. A total of 390 million dengue infections are estimated to occur per year,
and 3.97 billion people are estimated to be at risk of dengue infection worldwide [3, 4]. Throm-
bocytopenia induced by infection with dengue is typical around the time of defervescence and
is recognized as a potential indicator of clinical worsening according to the 2009 WHO guide-
lines [1, 2]. However, the underlying pathophysiological mechanisms involved in dengue-
induced thrombocytopenia remain controversial [5]. Recently, the Immature Platelet Fraction
(IPF%) and Immature Platelet Fraction Count (IPF#) have been recognized as measures of
thrombopoietic activity [6, 7]. Conceptually, IPF% and IPF# correspond respectively to the
percentage and absolute number of immature platelets in peripheral blood. Various studies
have evaluated the utility of these parameters in the evaluation of patients with haematological
conditions such as idiopathic thrombocytopenic purpura (ITP), thrombotic thromboctopenic
purpura (TTP), aplastic anaemia and chemotherapeutic related thrombocytopenia [6, 8]. It is
assumed that an increased IPF% indicates a consumptive or destructive thrombocytopenic sta-
tus; whereas a normal or decreased IPF% suggests decreased platelet production in bone mar-
row [9–11]. IPF# is considered to reflect real-time platelet production [7]. Although IPF% and
IPF# have been implemented in wider clinical settings, the benefit of evaluating these parame-
ters in patients with dengue infection has not been determined. Therefore, this study aimed to
investigate the thrombopoietic activity in patients with dengue infection by quantifying IPF%
and IPF# and to elucidate their characteristics by comparing with these parameters in patients
with community acquired bacterial infection (CABI). CABI was chosen as the control group
because the main topic of this study was the utility of IPF among febrile patients with throm-
bocytopenia. CABI-associated thrombocytopenia has clinically significant differences from
dengue; specifically, the need for antibiotic treatment and a poorer prognosis.
Materials and methods
This analysis was implemented under an existing study: “An observational study of commu-
nity acquired-bacteremia in San Lazaro Hospital, Manila, The Philippines”. San Lazaro Hospi-
tal is a national tertiary referral and training hospital for infectious diseases and has a 500-bed
capacity. This substudy comprised patients who were enrolled in the main study from May 1,
2017 to June 1, 2018 and satisfied eligibility criteria as follows: (i) admitted to San Lazaro Hos-
pital, (ii) aged� 1 year at admission, and (iii) having acute onset of fever (� 21 days) at admis-
sion. The participants were subsequently categorized into the three groups—confirmed
dengue infection, confirmed CABI, or suspected CABI–following the disease definitions
described below. Because limited diagnostic techniques were available at the study site and few
varieties of bacterial infectious diseases could be definitively diagnosed, the confirmed CABI
group was potentially weighted toward the diseases that were definitively diagnosable at the
study site. Therefore, the suspected CABI was included as a category to avoid selection bias.
Subjects were excluded if suspected of active tuberculosis or diagnosed with human immuno-
deficiency virus (HIV) infection. Participants were also excluded if unable to provide blood for
a complete blood count (CBC) test at admission or who received blood transfusion during
hospitalization.
PLOS ONE Immature platelet evaluation in dengue
PLOS ONE | https://doi.org/10.1371/journal.pone.0258936 November 1, 2021 2 / 15
Funding: This work was mostly supported by the
Ministry of Education, Culture, Sports, Science, and
Technology (MEXT), Government of Japan.
Department of Clinical Medicine, Institute of
Tropical Medicine, Nagasaki University has
received research fund from Sysmex Corporation
for the study: “An observational study of
community acquired-bacteremia in San Lazaro
Hospital, Manila, the Philippines” and the costs of
testing for this study were partially covered by the
research fund. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript. URL of
each funder website: https://www.mext.go.jp/en/
https://www.sysmex.co.jp/en/index.html.
Competing interests: The authors have no
conflicts of interest associated with Sysmex
Corporation relating to the employment,
consultancy, patents, products in development,
and marketed products. This does not alter our
adherence to PLoS ONE policies on sharing data
and materials.
Disease definition
Dengue diagnosis was established when the nonstructural protein 1 (NS1) antigen was positive
and/or dengue reverse transcriptase polymerase chain reaction (PCR) was positive without a pos-
itive blood culture result. Patients were also diagnosed with dengue if positive for dengue IgM
without laboratory positive results of other diseases or positive blood culture results. Diagnostic
criteria of each CABI are described in S1 Appendix. The CABI that fulfilled the diagnostic criteria
was categorize as confirmed CABI. Suspected CABI was a clinical diagnosis after excluding den-
gue infection but unable to reach a confirmed CABI diagnosis described in S1 Appendix.
Severe thrombocytopenia was defined as platelets <50×103/μl at admission or a platelet
nadir <50×103/μl during hospitalization in a time course evaluation. Non-severe thrombocy-
topenia was defined to include all patients with platelets�50×103/μl at admission or a platelet
nadir�50×103/μl during hospitalization in a time course evaluation.
Severe dengue was clinically defined as having at least one of the following conditions at
admission: systolic blood pressure�90 mmHg, desaturation requiring oxygenation, aspartate
aminotransferase� 1000 IU/L and/or alanine transaminase�1000 IU/L, or impaired con-
sciousness. Anemia was defined by hemoglobin levels at admission according to WHO guide-
lines [12].
NS1 antigen and dengue IgM were tested using a SD BIOLINE Dengue DuoTM kit (Stan-
dard Diagnostics, Korea). Laboratory procedure for diagnoses of CABIs are described in S2
Appendix. The details of PCR and ELISA method used in this study were as published [13–
17].
Laboratory procedure for IPF% and IPF#
Peripheral blood samples were drawn into tubes containing ethylene diamine tetra-acetic acid
(EDTA). In addition to regular CBC parameters, IPF% and IPF# were evaluated using an auto-
mated hematology analyzer (Sysmex XN-1000TM, Sysmex, Kobe, Japan). The analyzer detects
immature platelets, which are larger in size and contain more RNA than mature platelets, by
staining intracellular RNA with oxazine fluorescent dye. IPF% is expressed as a percentage rep-
resenting the ratio of the absolute number of immature platelets to the total number of plate-
lets. IPF# represents the absolute number of immature platelets per unit volume.
Data collection and statistical analysis
Age, demographic data and past medical history were documented at admission. The results
of the admission and subsequent CBC results of the patients were recorded in an electronic
data base. To evaluate the time course trend of platelet parameters, the representative values of
each parameter by day of illness were calculated using the results of participants who under-
went blood tests on a specific day of illness. The timing of blood collection varied between par-
ticipants and the sequential day-by-day test results were not available for everyone. We
defined the days of illness as the duration from the day of onset defined as day 0 of illness to
the day of interest. The clinicians or the researchers were not blinded to the laboratory results.
Baseline characteristics were compared using Fisher’s exact test for categorical variables or
the Mann Whitney test for continuous variables. Comparison of the results of dengue, con-
firmed CABI, and suspected CABI patients were performed using the Kruskal-Wallis test fol-
lowed by the Dunn’s post hoc test with Holm adjustment. Pairwise comparisons were
performed using the Mann Whitney test. P values of less than 0.05 were considered statistically
significant. All analyses were performed using Stata version 14.2 (Stata Corp., College Station,
TX, USA).
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Ethical issues
This work was conducted as a sub-study of a main study: “An observational study of commu-
nity acquired bacteremia in San Lazaro Hospital, Manila, The Philippines”. Ethical approval
for the main study was obtained from the Research Ethical and Review Unit of San Lazaro
Hospital, the Philippines (number: SLH-RERU-2015-005-E) and the Institutional Review
Board of the Institute of Tropical Medicine, Nagasaki University, Japan (number: 150226136–
4). Written informed consent was obtained from guardians or caregivers for patients aged
under 18 years of age, illiterate or unconscious at presentation. The requirements of the insti-
tutional review boards during the study period included obtaining written informed consent;
however, they did not include obtaining assent of the patients for whom guardians or caregiv-
ers provided written consent. For all others, written consent was obtained from the partici-
pants. The institutional review boards approved the consent procedures.
Results
1. Basic characteristics
The characteristics of participants at admission are summarized in Table 1. A total of 606
patients were eligible after excluding 19 subjects who satisfied the inclusion criteria but
received blood transfusion during treatment and one participant whose CBC test result was
not available at admission. The participants consisted of 152 patients suffering with dengue,
180 confirmed CABI and 274 suspected CABI patients. The confirmed diagnosis in the CABI
patients included leptospirosis (59 patients), X-ray confirmed pneumonia (37 patients), bacter-
emia (12 patients), diphtheria (25 patients), meningococcal disease (14 patients), and skin
infection (33 patients). The clinical diagnoses in the suspected CABI patients consisted of
pneumonia (72 patients), enteric fever (26 patients), urinary tract infection (23 patients), lepto-
spirosis (10 patients), central nervous system infection (8 patients), abdominal infection (4
patients), meningococcal disease (1 patient), septic rash (1 patient), and undiagnosable infec-
tious disease (129 patients). By definition, all suspected CABIs were diagnosed clinically and
no suspected CABI patient fulfilled the diagnostic criteria of confirmed CABIs. The median
age was 19.0 years (interquartile range (IQR): 13.0, 25.0) in the dengue group, 20.5 years (IQR:
9.0, 33.5) in the confirmed CABI group and 19.0 years (IQR: 10.0, 32.0) in the suspected CABI
group, and there were no significant differences between the dengue and each CABI group.
2. Comparison of platelet, IPF%, and IPF# at admission between the
dengue, confirmed CABI, and suspected CABI groups
Fig 1 shows the comparison of platelet, IPF% and IPF# at admission between the dengue, con-
firmed CABI and suspected CABI groups. The median day of illness at admission was 5 in all
groups and there was no significant difference among groups. (A) shows a comparison includ-
ing all participants. Platelet counts of the dengue group were significantly lower than those of
the confirmed CABI (median 88.0×103/μL versus 225.5×103/μL; p<0.001) and suspected
CABI groups (median 88.0×103/μL versus 221.0×103/μL; p<0.001). The IPF% of the dengue
group was significantly higher than those of the confirmed CABI (median 3.7% versus 1.9%; p
<0.001) and suspected CABI groups (median 3.7% versus 1.9%; p<0.001). Although there
was no significant difference of IPF# between the dengue group and the confirmed CABI
group (median 3.1×103/μL versus 3.9×103/μL; p = 0.057), the IPF# of the dengue group was
significantly lower than that of the suspected CABI group (median 3.1×103/μL versus 3.6×103/
μL; p = 0.005). The platelet parameters of each confirmed CABI are shown separately in S1
Fig. (B) shows a comparison including only the subgroups with severe thrombocytopenia
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<50×103/μL at admission. The median day of illness at admission was 5 for the three severe
thrombocytopenia groups and there was no significant difference among groups. There was
no significant difference of platelet counts among the three groups. Although the IPF% of the
dengue group remained significantly higher than that of the confirmed CABI group (median
9.5% versus 3.4%; p = 0.005), there was no significant difference of IPF% between the dengue
and the suspected CABI group (median 9.5% versus 6.9%; p = 0.247). The IPF# of the dengue
group was significantly higher than that of the confirmed CABI group (median 2.5×103/μL
Table 1. Basic characteristics of participants at admission.
Dengue (n = 152) Confirmed CABI (n = 180) p� Suspected CABI (n = 274) p�
n (%) or median (IQR) n (%) or median (IQR) n (%) or median (IQR)
Age 19.0 (13.0, 25.0) 20.5 (9.0, 33.5) 0.628 19.0 (10.0, 32.0) 0.985
Male 100 (65.8) 133 (73.9) 0.118 175 (63.9) 0.751
Mortality 1 (0.7) 22 (12.2) <0.001 9 (3.3) 0.104
Co-morbid conditions 17 (11.2) 42 (23.3) 0.004 78 (28.5) <0.001
Days of illness at admission
0–3 40 (26.3) 42 (23.3) 0.027 75 (27.4) <0.001
4,5 71 (46.7) 63 (35.0) 78 (28.5)
�6 38 (25.0) 72 (40.0) 114 (41.6)
unknown onset 3 (2.0) 3 (1.7) 7 (2.6)
Patients with anemia at admission 23 (15.1) 93 (51.7) <0.001 94 (34.3) <0.001
Routine hematology at admission
Platelets (103/μL) 88.0 (48.5, 161.5) 225.5 (100.0, 342.5) <0.001 221.0 (141.0, 316.0) <0.001
IPF% (%) 3.7 (1.6, 7.2) 1.9 (0.9, 3.5) <0.001 1.9 (1.0, 3.7) <0.001
IPF# (103/μL) 3.1 (1.9, 4.9) 3.9 (1.5, 7.0) 0.084 3.6 (2.4, 5.8) 0.002
WBC (103/μL) 4.2 (2.6, 6.5) 12.4 (8.3, 16.4) <0.001 8.3 (5.7, 12.6) <0.001
Neutrophils (103/μL) 1.8 (1.1, 3.3) 9.9 (5.9, 13.8) <0.001 5.5 (3.3, 9.4) <0.001
(%) 55.2 (35.5, 70.8) 79.0 (67.0, 87.5) <0.001 69.7 (54.6, 79.4) <0.001
Lymphocytes (103/μL) 1.1 (0.6, 2.4) 1.5 (0.7, 2.1) 0.543 1.6 (1.1, 2.4) <0.001
(%) 33.3 (20.0, 51.8) 12.5 (5.5, 21.5) <0.001 20.2 (12.1, 32.8) <0.001
Monocytes (103/μL) 0.4 (0.2, 0.6) 0.8 (0.5, 1.1) <0.001 0.7 (0.5, 1.1) <0.001
(%) 9.4 (6.6, 13.2) 6.4 (4.5, 8.8) <0.001 8.2 (5.9, 10.6) 0.002
Eosinophils (103/μL) 0.01 (0.00, 0.05) 0.04 (0.01, 0.19) <0.001 0.03 (0.00, 0.14) <0.001
(%) 0.4 (0.0, 1.0) 0.3 (0.0, 1.5) 0.136 0.3 (0.0, 1.9) 0.085
RBC (106/μL) 5.1 (4.7, 5.6) 4.5 (4.1, 4.9) <0.001 4.7 (4.4, 5.2) <0.001
Hemoglobin (g/dL) 138.0 (127.0, 152.5) 122.0 (108.5, 132.0) <0.001 126.0 (115.0, 140.0) <0.001
Hematocrit (%) 40.9 (38.7, 45.0) 36.9 (33.0, 40.0) <0.001 38.5 (34.6, 42.2) <0.001
AST (IU/L) 97.0 (57.0, 168.0) 32.0 (22.0, 59.0) <0.001 48.5 (28.0, 110.5) <0.001
ALT (IU/L) 58.0 (32.0, 118.0) 29.5 (20.0, 57.0) <0.001 44.0 (22.0, 82.0) 0.029
BUN (mg/dl) 9.8 (7.1, 12.6) 15.1 (10.2, 39.0) <0.001 9.4 (6.9, 13.8) 0.823
Creatinine (mg/dl) 0.8 (0.6, 0.9) 1.1 (0.6, 2.3) <0.001 0.8 (0.6, 1.1) 0.366
CRP (mg/L) 0.6 (0.1, 1.4) 11.5 (5.3, 16.0) <0.001 2.8 (0.9, 9.4) <0.001
PCT (ng/mL) 0.6 (0.3, 1.2) 2.2 (0.3, 10.0) <0.001 0.4 (0.1, 1.8) 0.052
� Between dengue and each CABI group using Fisher’s exact test for categorical variables or Mann Whitney test for continuous variables.
Missing number of participants in the dengue, confirmed CABI and suspected CABI group for AST = 89, 107, 170; ALT = 78, 84, 156; BUN = 83, 81, 153; Cre = 70, 71,
151; PCT = 6, 6, 17. CABI: community acquired bacterial infection, IQR: interquartile range, IPF%: Immature Platelet Fraction, IPF#: Immature Platelet Fraction Count.
WBC: white blood cell, RBC: red blood cell, AST: aspartate aminotransferase, ALT: alanine aminotransferase, BUN: blood urea nitrogen, CRP: C-reactive protein, PCT:
procalcitonin.
https://doi.org/10.1371/journal.pone.0258936.t001
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versus 0.8×103/μL; P = 0.007) but there was no significant difference of the IPF# between the
dengue and the suspected CABI group (median 2.5×103/μL versus 1.6×103/μL; p = 0.123).
3. Time course of platelet parameters by days of illness
Fig 2 shows the time course trends of platelet, IPF% and IPF# in the dengue, confirmed CABI
and suspected CABI groups from the first to tenth days of illness. The platelet counts of the
dengue group decreased from day 1, with a minimum observed on the sixth day of illness
before recovering to a normal level approximately on the tenth day of illness. The platelet
count of the two CABI groups shared a similar pattern, with a slightly increasing trend for the
whole duration. The IPF% of the dengue group increased from the start and peaked on the
sixth and seventh days, mirroring the pattern of the platelet count. The IPF% of the two CABI
groups remained level during the whole period. The IPF# of all three groups showed a gradual
Fig 1. Comparison of platelet, IPF% and IPF# among dengue, confirmed CABI, and suspected CABI groups at
admission. Horizontal lines show the median and interquartile ranges. (A) shows a comparison including all
participants and (B) shows a comparison including only the subgroups with severe thrombocytopenia<50×103/μL at
admission. Comparison of dengue, confirmed CABI and suspected CABI groups were performed using Kruskal-Wallis
test followed by the Dunn’s post hoc test with Holm adjustment. �: P<0.05, †: P<0.01, ‡: P<0.001. CABI: community
acquired bacterial infection, IPF%: Immature Platelet Fraction, IPF#: Immature Platelet Fraction Count.
https://doi.org/10.1371/journal.pone.0258936.g001
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increasing trend although the dengue group was slightly steeper. The line plot of the same data
is shown in S2 Fig. The time courses of the platelet parameters in the dengue group are shown
by age groups in S3 Fig and their trends were similar.
4. Comparison of platelet parameters among dengue, confirmed CABI, and
suspected CABI groups by specific time-phases
Fig 3 shows the comparison of platelet parameters among dengue, confirmed CABI, and sus-
pected CABI groups by three time-phases; febrile phase (day 1 to 3), critical phase (day 4 to 6),
and recovery phase (day 7 to 10). (A) shows a comparison including all participants. The
Fig 2. Time course trends of platelet parameters in each group from the first to tenth days of illness. Box and
whisker plots show the time course trends of platelet parameters in each group from the first to tenth days of illness.
Boxes show the median and interquartile values, whiskers represent the upper and lower adjacent values and dots
indicate outside values. The total numbers of evaluations included on each day are indicated on the X axis by each
group. CABI: community acquired bacterial infection, IPF%: Immature Platelet Fraction, IPF#: Immature Platelet
Fraction Count.
https://doi.org/10.1371/journal.pone.0258936.g002
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platelet counts of the dengue group were significantly lower than those of both the confirmed
and suspected CABI groups in all phases. There was no significant difference of IPF% between
dengue group and confirmed CABI group in the febrile phase (median 1.9% versus 2.4%;
p = 0.488), however, the IPF% of dengue group increased to be significantly higher than that of
the confirmed CABI in the critical phase (median 5.2% versus 2.2%; p <0.001) and recovery
phase (median 6.5% versus 2.2%; p<0.001). The IPF% of the dengue group was also signifi-
cantly higher than that of the suspected CABI groups in the critical and recovery phases. The
IPF# of the dengue group was significantly lower than those of the confirmed and suspected
CABI groups in the febrile and critical phases. S4 Fig shows a comparison including only the
subgroups with non-severe thrombocytopenia and significant differences of IPF% and IPF#
were also shown between dengue and the CABI groups in similar phases. (B) shows a compari-
son including only the subgroups with severe thrombocytopenia (defined as platelet nadir
<50×103/μl) during hospitalization. There were 67 dengue, 21 confirmed CABI and 25 sus-
pected CABI subjects with severe thrombocytopenia. The IPF% of the dengue group remained
significantly higher than that of the confirmed CABI group in the critical phase (median 8.2%
versus 2.0%; p<0.001) and recovery phases (median 9.2% versus 5.3%; p = 0.02) even though
there was no significant difference of platelet counts between the groups in the same phases.
The IPF% of the dengue group also remained significantly higher than that of the suspected
CABI group in the recovery phases. The IPF# of the confirmed CABI was significantly lower
than that of the dengue group in the critical phase despite no significant difference of platelet
counts between the groups in that same phase.
5. Comparison of platelet parameters between the severe
thrombocytopenia dengue group and the non-severe thrombocytopenia
dengue group by specific time-phases
Fig 4 shows the comparison of platelet parameters between the severe thrombocytopenia den-
gue group defined as platelet nadir <50×103/μl during hospitalization and the non-severe
thrombocytopenia dengue group defined to include all patients with a platelet nadir�50×103/
μl during hospitalization by specific time-phases. The platelet counts of the severe thrombocy-
topenia dengue group were significantly lower than those of the non-severe thrombocytopenia
dengue group in all phases. The IPF% of the severe thrombocytopenia dengue group was sig-
nificantly higher than that of the non-severe thrombocytopenia dengue group in the critical
phase (median 8.2% versus 3.8%; p<0.001) and recovery phases (median 9.2% versus 4.3%; p
<0.001). The IPF# of the severe thrombocytopenia dengue group was significantly lower than
that of the non-severe thrombocytopenia dengue group only in the critical phases. S5 Fig
shows a comparison between the severe and non-severe dengue groups (defined in the “Dis-
ease definition” section) There were 50 severe dengue subjects. For all platelet parameters
there was no significant difference between the severe dengue and non-severe dengue groups
in all phases.
Discussion
In this study we investigated the platelet parameters IPF% and IPF# in a dengue group at the
point of admission and during the course of hospitalization. Our evaluation revealed unique
platelet pattern parameters in the dengue group when compared with those of the confirmed
and suspected CABI groups. In brief, in a time course evaluation the IPF% of the patients with
dengue infection was significantly higher than those of the confirmed and suspected CABI
groups at admission and during the critical and recovery phases. When we considered only
those with severe thrombocytopenia, the IPF% of the dengue group remained significantly
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higher than those of the confirmed (at admission, and in the critical and recovery phases) and
suspected CABI groups (only in the recovery phase) even though their platelet levels were
comparable in the same phases. Similarly, the IPF# of the confirmed CABI group was lower
than that of the dengue group at admission and in the critical phase, with matching severity of
thrombocytopenia.
It is assumed that an increased IPF% indicates a consumptive or destructive thrombocyto-
penic status and a normal or decreased IPF% suggests decreased platelet production in bone
marrow. IPF# is assumed to reflect real-time platelet production [7, 18, 19]. However, one
study claimed that IPF# changes should be approached with caution because fluctuations
might be diminished by converting IPF% to absolute numbers in thrombocytopenia [20].
Fig 3. Comparison of platelet parameters among dengue, confirmed CABI, and suspected CABI groups by
specific time-phases. Box and whisker plots show the platelet parameters of dengue, confirmed CABI, and suspected
CABI groups observed in specific time-phases: febrile phase (day 1 to 3), critical phase (day 4 to 6), and recovery phase
(day 7 to 10). (A) shows a comparison including all participants and (B) shows a comparison including only the
subgroups with severe thrombocytopenia defined as platelet nadir<50×103/μl during hospitalization. Boxes show the
median and interquartile values, whiskers represent the upper and lower adjacent values and dots indicate outside
values. Comparison of dengue, confirmed CABI, and suspected CABI groups were performed using the Kruskal-
Wallis test followed by the Dunn’s post hoc test with Holm adjustment. �: P<0.05, †: P<0.01, ‡: P<0.001. CABI:
community acquired bacterial infection, IPF%: Immature Platelet Fraction, IPF#: Immature Platelet Fraction Count.
https://doi.org/10.1371/journal.pone.0258936.g003
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Fig 4. Comparison of platelet parameters between the severe and non-severe dengue thrombocytopenia groups by
specific time-phases. Box and whisker plots show the platelet parameters of the severe thrombocytopenia dengue
group defined as platelet nadir<50×103/μl during hospitalization and the non-severe thrombocytopenia dengue group
defined to include all patients with a platelet nadir�50×103/μl during hospitalization observed in specific time-phases:
febrile phase (day 1 to 3), critical phase (day 4 to 6), and recovery phase (day 7 to 10). Boxes show the median and
interquartile values, whiskers represent the upper and lower adjacent values and dots indicate outside values. The
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Moreover, immature platelets are also susceptible to consumption or destruction, which may
lower IPF# if the rate of platelet loss exceeds the pace of platelet production. Clinical interpre-
tations of IPF% and IPF# have been established based on observations mainly among hemato-
logic disorders. For example, high IPF% was reported in ITP and TTP, which are caused by
increased platelet consumption, while low to normal IPF% and low IPF# were documented in
aplastic anemia and chemotherapy-induced thrombocytopenia, which are caused by decreased
platelet production in bone marrow [6, 9, 11]. Low IPF# was observed in ITP with high IPF%,
which is compatible with the fact that ITP is a multifactorial autoimmune disease characterized
by both increased platelet destruction and/or reduced platelet production; and increased IPF#
was observed in ITP when treated by a thrombopoietin receptor agonist which increases plate-
let production [7, 9]. These observations support clinical interpretations of IPF% and IPF#.
Recently, IPF% and IPF# were further applied for infectious syndromes such as sepsis [21–23].
Hypotheses proposed regarding the underlying mechanisms of dengue-induced thrombo-
cytopenia are categorized mainly into two: decreased platelet production by bone marrow or
increased peripheral platelet consumption or destruction. Some previous studies proposed the
infection of hematopoietic progenitors or stromal cells as the causes of dengue-induced
decreased platelet production by bone marrow, and other studies proposed the anti-platelet
autoantibodies, the platelet-endothelial interaction, the platelet-leukocyte interaction, the
platelet-virus interaction or the soluble factors as the causes of dengue-induced increased
peripheral platelet consumption/destruction [24, 25]. In this study the IPF% of the dengue
group was significantly higher than those of confirmed and suspected CABI groups in critical
and/or recovery phases even after matching thrombocytopenia levels. Additionally, compari-
son between the severe thrombocytopenia and non-severe thrombocytopenia dengue groups
showed a significantly higher IPF% of the severe thrombocytopenia dengue group versus those
of other groups in the critical and recovery phases. Considering that IPF% reflects the balance
of two potential mechanisms—increased platelet consumption or destruction with high IPF%
and decreased platelet production with normal or low IPF%—these results suggest the pre-
dominance of increased peripheral platelet consumption or destruction over decreased platelet
production by bone marrow as an underlying mechanism of dengue-induced thrombocytope-
nia in the critical and recovery phases. Moreover, decreased platelet production by bone mar-
row might potentially co-exist with peripheral platelet consumption or destruction at the peak
of dengue-induced thrombocytopenia, because the comparison between the severe thrombo-
cytopenia dengue and the non-severe thrombocytopenia dengue groups showed a significantly
lower IPF# of the severe thrombocytopenia group versus those of other groups in the critical
phase. However, the IPF# need to be interpreted with caution because of the susceptivity of
immature platelets to consumption or destruction as mentioned above. Because the IPF% and
the IPF# of the confirmed CABI group were significantly lower than that of dengue in the criti-
cal phase after matching the thrombocytopenia levels, the suppression of platelet production
by bone marrow seems to be more predominant in CABI-induced than in dengue-induced
thrombocytopenia.
Drawing from their utility in hematologic disorders, IPF% and IPF# offer insight into den-
gue-induced thrombocytopenia as well as provide information for the clinical management of
dengue patients. Our results show differences of IPF% and IPF# between dengue and the
CABI groups. IPF% and IPF# are potentially valuable parameters for the differential diagnosis
of dengue from CABI especially in patients with thrombocytopenia. Further study is warranted
comparison between each pair of dengue subgroups were performed using the Mann Whitney test. �: P<0.05, †:
P<0.01, ‡: P<0.001. IPF%: Immature Platelet Fraction, IPF#: Immature Platelet Fraction Count.
https://doi.org/10.1371/journal.pone.0258936.g004
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to analyze the performance of IPF as a biomarker for the differential diagnosis of dengue from
CABI.
This study has some limitations. Sequential day-by-day test results were not available for all
patients, and this may introduce overestimation when severe patients were tested more fre-
quently. There may be unreliability in patient reported onset day of symptoms. Because of the
limited diagnostic techniques available at the study site, few varieties of bacterial infectious dis-
eases could be included as confirmed CABI. Not all pneumonia-suspected patients underwent
X-ray tests at the study site because of the limited resources. We rigorously judged the exis-
tence of radiographic shadowing for high specificity, which might reduce the number of X-ray
confirmed pneumonia cases. It was difficult to include confirmed urinary tract infections
because a clean catch urine collection was technically difficult and bacterial contamination
occurred very frequently at the study site. Detailed investigations were not available at the
study site to determine possible primary or secondary dengue infections and dengue serotypes.
We could not check serum thrombopoietin, the main factor for regulating thrombopoiesis.
Although disseminated intravascular coagulation (DIC) might influence the IPF results, the
coagulation studies to assess DIC were not available at the study site. This was a single-center
study and further data accumulation is required in various countries and clinical settings to
validate our findings.
This study demonstrated the distinctive characteristics and time-course trends of IPF% and
IPF# in a dengue group, which were significantly different compared with those of confirmed
and suspected CABI groups. IPF% and IPF# are potentially valuable parameters in dengue and
further investigation is required for the optimal use in clinical practice.
Supporting information
S1 Fig. Comparison of platelet, IPF%, and IPF# among dengue and each confirmed CABI
at admission. The lines show the median with interquartile ranges. Comparisons of each
group were performed using the Kruskal-Wallis test followed by the Dunn’s post hoc test with
Holm adjustment. �: P<0.05, †: P<0.01, ‡: P<0.001. IPF%: Immature Platelet Fraction, IPF#:
Immature Platelet Fraction Count.
(TIF)
S2 Fig. Time course trends of platelet parameters in each group from the first to tenth
days of illness (line plot). Data are expressed as mean with a 95% confidence interval shown
by the error bars. The total number of evaluations included on each day is indicated on the X
axis by each group. The mean of each platelet parameter by days of illness were calculated
from the results of participants who underwent a blood test on each day. CABI: community
acquired bacterial infection, IPF%: Immature Platelet Fraction, IPF#: Immature Platelet Frac-
tion Count.
(TIF)
S3 Fig. Time course of platelet parameters in the dengue group by age groups. Box and
whisker plots show the time course trends of platelet parameters in the dengue group by age
from the first to tenth days of illness. Boxes show the median and interquartile values, whiskers
represent upper and lower adjacent values and dots indicate outside values. The total number
of evaluations included on each day is indicated on the X axis by each group. IPF%: Immature
Platelet Fraction, IPF#: Immature Platelet Fraction Count.
(TIF)
S4 Fig. Comparison of platelet parameters among dengue, confirmed CABI, and suspected
CABI groups including only the subgroups with non-severe thrombocytopenia by specific
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time-phases. Box and whisker plots show the platelet parameters of dengue, confirmed CABI,
and suspected CABI groups observed in specific time-phases: febrile phase (day 1 to 3), critical
phase (day 4 to 6), and recovery phase (day 7 to 10). Non-severe thrombocytopenia was
defined as a platelet nadir�50×103/μl during hospitalization. Boxes show the median and
interquartile values, whiskers represent the upper and lower adjacent values and dots indicate
outside values. Comparison of dengue, confirmed CABI, and suspected CABI groups were
performed using the Kruskal-Wallis test followed by the Dunn’s post hoc test with Holm
adjustment. �: P<0.05, †: P<0.01, ‡: P<0.001. CABI: community acquired bacterial infection,
IPF%: Immature Platelet Fraction, IPF#: Immature Platelet Fraction Count.
(TIF)
S5 Fig. Comparison of platelet parameters between the severe and non-severe dengue
groups by specific time-phases. Box and whisker plots show the platelet parameters of severe
and non-severe dengue groups observed in specific time-phases; febrile phase (day 1 to 3), crit-
ical phase (day 4 to 6) and recovery phase (day 7 to 10). Severe dengue was clinically defined in
the “Disease definition” section. Boxes show the median and interquartile values, whiskers rep-
resent the upper and lower adjacent values and dots indicate outside values. Comparisons
between each pair of dengue subgroups were performed using the Mann Whitney test. IPF%:
Immature Platelet Fraction, IPF#: Immature Platelet Fraction Count.
(TIF)
S1 Table. Comparison of the results from real-time PCR (rrs real-time PCR) and flaB-
nested PCR. A total number of 50 negative samples and 43 positive samples for flaB-nested
PCR were tested in duplicate by rrs real-time PCR. The 50 negative samples for flaB-nested
PCR were also negative for the microscopic agglutination test using paired sera. This rrs real-
time PCR did not detect bacterial species other than Leptospira spp. described in published
study [17]. rrs: 16S ribosomal RNA gene.
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